Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome-A Prospective Longitudinal Multicentre Study

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2024 Oct 18

PMID 39422092

Authors

Elsa L S A van Liere

Dewkoemar Ramsoekh

Emma Daulton

Maya Dakkak

Joris M van Lingen

Trenton K Stewart

Sofie Bosch

Beatriz Carvalho

Evelien Dekker

Maarten A J M Jacobs

Jan Jacob Koornstra

Johan P Kuijvenhoven

Monique E van Leerdam

Tim G J de Meij

Gerrit A Meijer

Manon C W Spaander

James A Covington

Nanne K H de Boer

Affiliations

Soon will be listed here.

Abstract

Background: Non-invasive biomarkers may reduce post-colonoscopy colorectal cancer (CRC) rates and colonoscopy overuse in Lynch syndrome. Unlike faecal immunochemical test (FIT), faecal volatile organic compounds (VOCs) may accurately detect both advanced and non-advanced colorectal neoplasia.

Aim: The aim of this study was to evaluate the potential of faecal VOCs-separately and with FIT-to guide optimal colonoscopy intervals in Lynch syndrome.

Methods: Prospective longitudinal multicentre study in which individuals with Lynch syndrome collected faeces before and after high-quality surveillance colonoscopy. VOC-patterns were analysed using field asymmetric ion mobility spectrometry (FAIMS) and gas chromatography-ion mobility spectrometry (GC-IMS) followed by machine learning pipelines, and combined with FIT at 2.55 μg Hb/g faeces. Gas chromatography time-of-flight mass spectrometry analysed individual VOC abundance.

Results: Among 200 included individuals (57% female, median 51 years), 62 had relevant neoplasia at colonoscopy: 3 CRC, 6 advanced adenoma (AA), 3 advanced serrated lesion (ASL), and 50 non-advanced adenoma (NAA). Respective sensitivity and negative predictive value for CRC and AA (and also ASL in case of FAIMS) were 100% and 100% using FAIMS (54% specificity), and 89% and 99% using GC-IMS (58% specificity). Respective sensitivity and specificity for any relevant neoplasia were 88% and 44% (FAIMS) and 84% and 28% (GC-IMS); accuracy did not significantly improve upon VOC-FIT. VOC-patterns differed before and after polypectomy (AUC 0.70). NAA showed decreased faecal abundance of butanal, 2-oxohexane, dimethyldisulphide and dimethyltrisulphide.

Conclusions: In Lynch syndrome, faecal VOCs may be a promising strategy for postponing colonoscopy and for follow-up after polypectomy. Our results serve as a stepping stone for large validation studies.

Trial Registration: NL8749.

References

Zhao S, Wang S, Pan P, Xia T, Chang X, Yang X . Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. 2019; 156(6):1661-1674.e11. DOI: 10.1053/j.gastro.2019.01.260. View

Rex D, Ahnen D, Baron J, Batts K, Burke C, Burt R . Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107(9):1315-29. PMC: 3629844. DOI: 10.1038/ajg.2012.161. View

Rivero-Sanchez L, Arnau-Collell C, Herrero J, Remedios D, Cubiella J, Garcia-Cougil M . White-Light Endoscopy Is Adequate for Lynch Syndrome Surveillance in a Randomized and Noninferiority Study. Gastroenterology. 2019; 158(4):895-904.e1. DOI: 10.1053/j.gastro.2019.09.003. View

Bosch S, Lemmen J, Menezes R, van der Hulst R, Kuijvenhoven J, Stokkers P . The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. J Breath Res. 2019; 13(4):046001. DOI: 10.1088/1752-7163/ab2775. View

van Keulen K, Jansen M, Schrauwen R, Kolkman J, Siersema P . Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer. Aliment Pharmacol Ther. 2019; 51(3):334-346. PMC: 7003780. DOI: 10.1111/apt.15622. View

Berwald G, Young G, Cock C, Bampton P, Fraser R, Symonds E . The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy. Clin Gastroenterol Hepatol. 2023; 22(4):878-885.e2. DOI: 10.1016/j.cgh.2023.09.016. View

van Liere E, de Boer N, Dekker E, van Leerdam M, de Meij T, Ramsoekh D . Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Aliment Pharmacol Ther. 2022; 55(7):778-788. PMC: 9303645. DOI: 10.1111/apt.16824. View

Moradi-Marjaneh R, Hassanian S, Mehramiz M, Rezayi M, Ferns G, Khazaei M . Reactive oxygen species in colorectal cancer: The therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways. J Cell Physiol. 2018; 234(7):10072-10079. DOI: 10.1002/jcp.27881. View

Holme O, Bretthauer M, Eide T, Loberg E, Grzyb K, Loberg M . Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2014; 64(6):929-36. DOI: 10.1136/gutjnl-2014-307793. View

10.

Widlak M, Neal M, Daulton E, Thomas C, Tomkins C, Singh B . Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018; 20(12):O335-O342. DOI: 10.1111/codi.14431. View

11.

Smielowska M, Ligor T, Kupczyk W, Szeliga J, Jackowski M, Buszewski B . Screening for volatile biomarkers of colorectal cancer by analyzing breath and fecal samples using thermal desorption combined with GC-MS (TD-GC-MS). J Breath Res. 2023; 17(4). DOI: 10.1088/1752-7163/ace46e. View

12.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

13.

Meester R, van Herk M, Lansdorp-Vogelaar I, Ladabaum U . Prevalence and Clinical Features of Sessile Serrated Polyps: A Systematic Review. Gastroenterology. 2020; 159(1):105-118.e25. PMC: 8653879. DOI: 10.1053/j.gastro.2020.03.025. View

14.

Woodfield G, Belluomo I, Laponogov I, Veselkov K, Cross A, Hanna G . Diagnostic Performance of a Noninvasive Breath Test for Colorectal Cancer: COBRA1 Study. Gastroenterology. 2022; 163(5):1447-1449.e8. DOI: 10.1053/j.gastro.2022.06.084. View

15.

Wu D, Mou Y, Chen K, Cai J, Zhou Y, Pan Y . Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis. Int J Oncol. 2016; 49(2):611-22. DOI: 10.3892/ijo.2016.3551. View

16.

de Swart J, van Gaal N, Berkhout D, de Meij T, de Boer N . Smoking Influences Fecal Volatile Organic Compounds Composition. Clin Gastroenterol Hepatol. 2017; 16(7):1168-1169. DOI: 10.1016/j.cgh.2017.11.002. View

17.

Bosch S, Berkhout D, Ben Larbi I, de Meij T, de Boer N . Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?. J Cancer Res Clin Oncol. 2018; 145(1):223-234. DOI: 10.1007/s00432-018-2821-3. View

18.

OBrien P, Siraki A, Shangari N . Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol. 2006; 35(7):609-62. DOI: 10.1080/10408440591002183. View

19.

Bosch S, El Manouni El Hassani S, Covington J, Wicaksono A, Bomers M, Benninga M . Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry. Anal Chem. 2018; 90(13):7972-7981. PMC: 6143285. DOI: 10.1021/acs.analchem.8b00688. View

20.

Palmer C, Thomas M, von Wagner C, Raine R . Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br J Cancer. 2014; 110(7):1705-11. PMC: 3974074. DOI: 10.1038/bjc.2014.125. View